Sevadar Foundation Inc. · 501(c)(3)
Compassion and compliance are not opposites
IntellaRx is a program for public agencies working on the opioid crisis. It supplies the clinical context that prescription-count analysis does not have, and it closes the identification gap that makes diversion possible.
The problem in one paragraph
Two decades of policy has been aimed at the number of opioid prescriptions written. That number came down. Overdose mortality did not follow it down — it rose for years afterward, driven by an illicit supply that prescribing rules do not touch. Meanwhile the analysis used to find bad actors reads prescription counts and doses without knowing a patient’s diagnosis or the treating clinician’s intent, so it cannot distinguish a pill mill from a specialist who legitimately treats the most complex patients in a region. Patients caught in the middle lose access to care. Diversion, the thing everyone is trying to prevent, remains possible because nobody positively identifies who actually receives a controlled medication.
IntellaRx addresses both halves of that. Read the full argument.
What IntellaRx does
Supplies clinical context
Diagnosis, treatment plan, prior therapy, comorbidity and metabolic profile — the information that turns a prescription count into a clinical picture. ProviderSynch · Metabolic determination
Closes the identification gap
Confirms that the person receiving a controlled medication is the person it was prescribed to — which is what prevents diversion, identity theft and misattributed test results. Biometric cross-validation · DNALock
Watches the supply, not the patient
Population-level analysis of what is circulating in a region and what is killing people in it — so an agency can act on a change in the drug supply within days rather than quarters. Emerging threat analysis
Built on the federal consensus, not around it
The Comprehensive Addiction and Recovery Act of 2016 created the Pain Management Best Practices Inter-Agency Task Force. Its recommendations are the frame this program is built on: a biopsychosocial model of care, individualized and patient-centered treatment, safer opioid stewardship through risk assessment grounded in a patient’s medical, social and family history, and a multidisciplinary approach that treats behavioral health alongside physical pain. See the evidence base, including the parts of it that are thin.
Honest about the evidence
Some of what this program does rests on solid ground. Some does not, and we say which is which. A federally funded systematic review found a lack of evidence that urine drug testing is effective for risk mitigation in opioid prescribing, and documented that results can be misread in ways that harm patients. That is on our urine drug testing page, not buried. An agency deciding how to spend public money deserves to know where the floor is.
Who this is for
IntellaRx works with public agencies — health departments, Medicaid programs, corrections and reentry health services, county and municipal public-health authorities, and the multi-agency task forces they convene. It is not a consumer service. How engagement works.
Talk to us
Tell us what you are trying to change and we will tell you plainly whether this program helps.